Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Cytosorbents (CTSO) Leases (2018 - 2026)

Cytosorbents filings provide 8 years of Leases readings, the most recent being $10.9 million for Q4 2025.

  • On a quarterly basis, Leases fell 5.1% to $10.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.9 million, a 5.1% decrease, with the full-year FY2025 number at $10.9 million, down 5.1% from a year prior.
  • Leases hit $10.9 million in Q4 2025 for Cytosorbents, down from $11.1 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $13.7 million in Q3 2021 to a low of $923960.0 in Q1 2021.
  • Median Leases over the past 5 years was $12.1 million (2023), compared with a mean of $11.7 million.
  • The widest YoY moves for Leases: up 1328.29% in 2022, down 6.28% in 2022.
  • Cytosorbents' Leases stood at $13.4 million in 2021, then decreased by 6.11% to $12.6 million in 2022, then decreased by 4.32% to $12.1 million in 2023, then dropped by 4.54% to $11.5 million in 2024, then dropped by 5.1% to $10.9 million in 2025.
  • The last three reported values for Leases were $10.9 million (Q4 2025), $11.1 million (Q3 2025), and $11.2 million (Q2 2025) per Business Quant data.